1. Marshall LM, Spiegelman D, Barbieri RL, Goldman MB, Manson JE, Colditz GA, et al. Variation in the incidence of uterine leiomyoma among premenopausal women by age and race. Obstet Gynecol. 1997; 90:967–973.
2. Schwartz SM. Epidemiology of uterine leiomyomata. Clin Obstet Gynecol. 2001; 44:316–326.
3. Hee LC. Uterine myoma : review of 247 cases. Korean J Obstet Gynecol. 1968; 11:65–73.
4. Sue HS, Nam C, Kim CS, Jang BK, Yang HD, Park SJ. A clinico-statstical study on the myoma of the uterus. Korean J Obstet Gynecol. 1996; 39:1047–1057.
5. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA. 2002; 288:321–333.
6. Ang WC, Farrell E, Vollenhoven B. Effect of hormone replacement therapies and selective estrogen receptor modulators in postmenopausal women with uterine leiomyomas: a literature review. Climacteric. 2001; 4:284–292.
7. Stewart EA. Uterine fibroids. Lancet. 2001; 357:293–298.
8. Colacurci N, De Franciscis P, Cobellis L, Nazzaro G, De Placido G. Effects of hormone replacement therapy on postmenopausal uterine myoma. Maturitas. 2000; 35:167–173.
9. de Aloysio D, Altieri P, Penacchioni P, Salgarello M, Ventura V. Bleeding patterns in recent postmenopausal outpatients with uterine myomas: comparison between two regimens of HRT. Maturitas. 1998; 29:261–264.
10. Fedele L, Bianchi S, Raffaelli R, Zanconato G. A randomized study of the effects of tibolone and transdermal estrogen replacement therapy in postmenopausal women with uterine myomas. Eur J Obstet Gynecol Reprod Biol. 2000; 88:91–94.
11. Palomba S, Sena T, Noia R, Di Carlo C, Zullo F, Mastrantonio P. Transdermal hormone replacement therapy in postmenopausal women with uterine leiomyomas. Obstet Gynecol. 2001; 98:1053–1058.
12. Polatti F, Viazzo F, Colleoni R, Nappi RE. Uterine myoma in postmenopause: a comparison between two therapeutic schedules of HRT. Maturitas. 2000; 37:27–32.
13. Sener AB, Seckin NC, Ozmen S, Gökmen O, Doğu N, Ekici E. The effects of hormone replacement therapy on uterine fibroids in postmenopausal women. Fertil Steril. 1996; 65:354–357.
14. Simsek T, Karakus C, Trak B. Impact of different hormone replacement therapy regimens on the size of myoma uteri in postmenopausal period: tibolone versus transdermal hormonal replacement system. Maturitas. 2002; 42:243–246.
15. Yang CH, Lee JN, Hsu SC, Kuo CH, Tsai EM. Effect of hormone replacement therapy on uterine fibroids in postmenopausal women--a 3-year study. Maturitas. 2002; 43:35–39.
16. Maruo T, Ohara N, Wang J, Matsuo H. Sex steroidal regulation of uterine leiomyoma growth and apoptosis. Hum Reprod Update. 2004; 10:207–220.
17. Chrapusta S, Sieinski W, Konopka B, Szamborski J, Paszko Z. Estrogen and progestin receptor levels in uterine leiomyomata: relation to the tumour histology and the phase of menstrual cycle. Eur J Gynaecol Oncol. 1990; 11:381–387.
18. Rein MS. Advances in uterine leiomyoma research: the progesterone hypothesis. Environ Health Perspect. 2000; 108:Suppl 5. 791–793.
19. Tamaya T, Fujimoto J, Okada H. Comparison of cellular levels of steroid receptors in uterine leiomyoma and myometrium. Acta Obstet Gynecol Scand. 1985; 64:307–309.
20. Schwartz SM, Weiss NS, Daling JR, Gammon MD, Liff JM, Watt J, et al. Exogenous sex hormone use, correlates of endogenous hormone levels, and the incidence of histologic types of sarcoma of the uterus. Cancer. 1996; 77:717–724.
21. Palomba S, Sena T, Morelli M, Noia R, Zullo F, Mastrantonio P. Effect of different doses of progestin on uterine leiomyomas in postmenopausal women. Eur J Obstet Gynecol Reprod Biol. 2002; 102:199–201.
22. Giuntoli RL 2nd, Metzinger DS, DiMarco CS, Cha SS, Sloan JA, Keeney GL, et al. Retrospective review of 208 patients with leiomyosarcoma of the uterus: prognostic indicators, surgical management, and adjuvant therapy. Gynecol Oncol. 2003; 89:460–469.
23. Leibsohn S, d'Ablaing G, Mishell DR Jr, Schlaerth JB. Leiomyosarcoma in a series of hysterectomies performed for presumed uterine leiomyomas. Am J Obstet Gynecol. 1990; 162:968–974. discussion 74-6.